Image from the 22nd February 2017 of a billboard that announces that Nasdaq Stockholm welcomes Oncopeptides.

Investor news

Filter by year

Oncopeptalks on the recent FDA decision

February 27, 2024
Read more

Invitation to presentation of the year-end report 2023

February 21, 2024
February 21, 2024 – Oncopeptides AB (publ) will publish the report for the fourth quarter and the 2023 year-end report on February 27, 2024. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session at 09:00 CET on the same day.
Read more

Oncopeptalks on the treatment landscape and competition

January 29, 2024
January 29, 2024 - Join David and Sofia for the first Oncopeptalks of the year – where Sofia deep dives into the rapidly changing treatment landscape for multiple myeloma and where Pepaxti is positioned versus its competitors.
Read more

Oncopeptides’ investor presentation and panel at Redeye published

January 26, 2024
January 26, 2024 - Earlier this week, Oncopeptides CEO Sofia Heigis presented at the Fight Cancer event hosted by investment bank Redeye. The company presentation was followed by a panel discussion together with Xpray Pharma CEO Per Andersson on the topic of commercialization and market access. Watch the presentation.
Read more

Sofia Heigis to present at Redeye Fight Cancer on January 24

January 22, 2024
January 24, 2024 - Sofia Heigis, CEO of Oncopeptides, will present Oncopeptides at the Redeye Fight Cancer event on January 24. Apart from individual company presentations the event includes Q and A-sessions with each company as well as panel discussions.
Read more

Henrik Bergentoft to present at Aktiespararna Södertälje on January 22

January 22, 2024
January 22, 2024 - Henrik Bergentoft, CFO of Oncopeptides, will present Oncopeptides at an Aktiespararna Södertälje investor event on January 22. The event is by invitation only.
Read more

End of year Oncopeptalks published

December 20, 2023
December 20, 2023 - CEO Sofia Heigis and IR Director David Augustsson cover the appeal in the U.S., sales in Europe in 2024 and beyond as well as share some highlights from this year’s ASH meeting.
Read more

The Q3 Earnings episode of Oncopeptalks

November 15, 2023
November 15, 2023 - David Augustsson, Director, Corporate Affairs, and CEO Sofia Heigis are leading this edition of Oncopeptalks.
Read more

The third episode of Oncopeptalks - Industry Congresses

October 20, 2023
October 20, 2023 - Join David Augustsson, Director of Corporate Affairs at Oncopeptides, for the third episode of Oncopeptalks together with CEO Sofia Heigis.
Read more

New information regarding Oncopeptides’ appeal of U.S. withdrawal published

September 21, 2023
Additional information regarding the formal request from the U.S. Food and Drug Administration (FDA) to voluntarily withdraw Pepaxto’s approval in the U.S has been made available in the public docket. More information and Q&A.
Read more

Oncopeptides launches "Oncopeptalks" with a fireside chat featuring CEO Sofia Heigis

September 20, 2023
Join David Augustsson, Director, Corporate Affairs at Oncopeptides, for the first edition of Oncopeptalks – a short company update aimed at investors where various members of the Oncopeptides team will be able to answer questions and address issues from the investor community.
Read more

CEO Sofia Heigis presented to Aktiespararna at Aktiedagen in Stockholm

September 19, 2023
On Tuesday, September 19, Sofia Heigis presented Oncopeptides at Aktiedagen in Stockholm, an event organized by Aktiespararna. The presentation can be viewed here and is available in Swedish only.
Read more

CHMP issues positive opinion on Type II variation to extend the therapeutic indication of Pepaxti based on OCEAN trial results

September 14, 2023
Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has, following their scientific assessment, adopted a positive opinion on Oncopeptides’ application for earlier lines of treatment for patients with relapsed, refractory multiple myeloma (RRMM). The opinion from the CHMP will now be sent to the European Commission for a final decision.
Read more

Stefan Norin named Chief Medical Officer at Oncopeptides

September 1, 2023
Oncopeptides today announces that Stefan Norin has been promoted to new Chief Medical Officer (CMO) at Oncopeptides, effective immediately.
Read more

Information regarding Oncopeptides’ appeal of U.S. withdrawal published

August 25, 2023
On August 25, 2023, more information regarding the formal request from the U.S. Food and Drug Administration (FDA) to voluntarily withdraw Pepaxto's approval in the U.S has been made available by the FDA.
Read more

Webcast - Presentation of the Q2 report 2023

August 6, 2023
Oncopeptides will publish the report for the second quarter 2023, at 08.00 (CET) on Thursday August 10, 2023, and will host a webcast on the same day at 09:00 (CET). Investors, financial analysts, and media are invited to participate in the webcast and following Q&A.
Read more

Oncopeptides complete first sales of Pepaxti in Greece

June 19, 2023
Oncopeptides today announced its first named patient sales of its flagship drug Pepaxti in Greece. The sales were made possible through Oncopeptides’ partnership with Ariti S.A., a company specialized on medical and pharmaceutical supply in Greece.
Read more

Presentation of the Q1 Interim report 2023

May 2, 2023
Oncopeptides AB (publ) published the report for the first quarter 2023, at 08.00 (CET) on Thursday May 4, 2023. Investors, financial analysts, and media were invited to participate in a webcast and a following QnA session at 09.00 (CET) on the same day.
Read more

Presentation of the year-end report 2022

February 9, 2023
Oncopeptides AB (publ) published the report for the fourth quarter and the 2022 year-end report, on February 16, 2023. Investors, financial analysts, and media were invited to participate in a webcast and a following QnA session on the same day. The event was hosted by Monica Shaw, CEO, together with Holger Lembrér, CFO, and Jakob Lindberg, CSO. The presentation was held in English.
Read more

DNB Healthcare Conference 2022 - presentation

December 15, 2022
On December 15, 2022, Oncopeptides CCO and Managing Director Germany, Sofia Heigis, gave a presentation at the DNB Healthcare Conference in Oslo, together with Dr. Fredrik Schjesvold from the Oslo Myeloma Center.
Read more

Fire side chat with CEO Jakob Lindberg at SEB's Annual Healthcare Seminar 2022

November 23, 2022
At SEB's Annual Healthcare Seminar 2022 Jakob Lindberg, CEO Oncopeptides, participated in a fire side chat with Dr. Christopher Uhde, Pharma/Biotec equity research at SEB.
Read more

Webcast - presentation of the Q3 report 2022

November 7, 2022
Oncopeptides published its report for the third quarter 2022 on November 9 at 08.00 (CET). On the same day at 14:00 (CET) investors, analysts, and media were invited to participate in a webcast and a following QnA session. The event was hosted by Chief Executive Officer Jakob Lindberg, together with Chief Commercial Officer Sofia Heigis and Chief Financial Officer Annika Muskantor. The presentations was held in English.
Read more

German launch - press conference

October 21, 2022
Friday October 21, 2022, Oncopeptides held a press conference to talk about the German launch of Pepaxti®.
Read more

Webcast - update from the ODAC meeting, Sep 22

September 23, 2022
September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population.
Read more

Webcast - presentation of the Q2 Interim Report 2022

August 9, 2022
Oncopeptides published its report for the second quarter 2022 on August 11, 2022, and hosted a webcast on the same day at 14:00 CET.
Read more

Webcast - CHMP rekommenderar att Oncopeptides Pepaxti får ett fullt godkännande i EU

June 23, 2022
June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.
Read more

CEO sitdown with Jakob - webcast June 1, 2022

June 1, 2022
CEO Jakob Lindberg took part in a webcast called CEO sitdown at Paues Åberg June 1, 2022. The interview is moderated by Caroline Wiken, partner at Paues Åberg.
Read more

ABGSC Life Science Summit 2022 - presentation

May 19, 2022
Oncopeptides CEO Jakob Lindberg presented at the ABGSC Life Science Summit 2022, May 19.
Read more

Webcast - Presentation of the Q1 Interim Report 2022

May 4, 2022
Oncopeptides published its report for the first quarter 2022 on May 4, 2022, and hosted a webcast on the same day.
Read more

Carnegie Healthcare Seminar 2022

March 17, 2022
Oncopeptides CEO Jakob Lindberg presented at Carnegie Healthcare Seminar 2022, March 17 at 16.45 CET. See the presentation below.
Read more

Webcast - Presentation of the Year-end Report 2021

February 17, 2022
Oncopeptides published its report for the fourth quarter and year-end results 2021 on February 17, 2022, and hosted a webcast on the same day.
Read more

Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto

January 21, 2022
Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US. Investors, financial analysts and media were invited to participate in a webcast with a Q&A session on January 24, 2022
Read more

Webcast - Presentation of the Q3 Interim Report 2021

November 24, 2021
Oncopeptides published its report for the third quarter 2021 on November 24, 2021, and hosted a webcast on the same day.
Read more

Jakob interviewed by Di.TV - as new CEO about going forward

November 15, 2021
In conjunction with the announcement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.
Read more

Webcast - Oncopeptides withdraw Pepaxto® in US, scale down organization and focus on R&D

October 22, 2021
October 22, 2021, Oncopeptides announced that the company has decided to withdraw Pepaxto® from the market in the US. The decision has been made after interactions and dialogue with the US Food and Drug Administration, FDA.
Read more

Handelsbanken Healthy Hour - presentation

September 15, 2021
Oncopeptides presented at Handelsbanken Healthy Hour on September 15. The presentation was held by CEO Marty J Duvall, CSO Klaas Bakker and CFO Anders Martin-Löf.
Read more

Webcast for presentation of OCEAN data presented at IMW

September 12, 2021
Oncopeptides presented data from the OCEAN study at the 18th International Myeloma Workshop (IMW) on September 11. Investors, financial analysts, and media were invited to participate in a webcast including a Q&A on September 12.
Read more

Presentation of the Q2 Interim Report 2021

August 19, 2021
Oncopeptides has published its report for the second quarter 2021 on August 19, 2021, and hosted a webcast on the same day at 12:00 CEST.
Read more

Presentation updated OCEAN data

July 8, 2021
Oncopeptides hosted a webcast on July 8, 2021, at 11:00 (CET) including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, and CMO Klaas Bakker.
Read more

Redeye Growth Day 2021 presentation

June 2, 2021
Oncopeptides' CFO Anders Martin-Löf presented at Redeye Growth Day 2021 , June 2.
Read more

Presentation of the Q1 Interim Report 2021

May 26, 2021
Oncopeptides has published the Q1 Interim Report 2021 and hosted a webcast the same day at 12:00 (CET), May 26, 2021.
Read more

Webcast - presentation of OCEAN topline data, May 25, 2021

May 25, 2021
In conjunction with the release of the topline data of the OCEAN study, Oncopeptides hosted a webcast May 25, 2021, at 11:00 (CET), including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas Bakker, and CFO Anders Martin-Löf.
Read more

Theme Day Commercialization of Medicine - Erik Penser Bank

May 6, 2021
Oncopeptides' CFO Anders Martin-Löf presented at Erik Penser Bank's theme day Commercialization of medical component on May 6 at 16:15 CET. The theme day was broadcasted live 09:00-17:00 CET.
Read more

Aktiedagen Stockholm - Aktiespararna

May 4, 2021
Oncopeptides' CFO Anders Martin-Löf presented at Aktiespararna's event Aktiedagen Stockholm on May 4 at 13:30 CET. The share day was broadcasted live from 07: 50-20:00 CET and 18 listed companies participated.
Read more

Cowen 41st Annual Health Care Conference - presentation

March 3, 2021
Oncopeptides' CEO Marty J Duvall presented at the Cowen 41st Annual Health Care Conference, March 3, 2021, at 17.00 CET.
Read more

Company Presentation March 2021

March 3, 2021
New Company Presentation for Oncopeptides, March 2021.
Read more

FDA approval of PEPAXTO - Webcast for investors, analysts and the media

March 1, 2021
In conjunction with the FDA approval of PEPAXTO February 26, Oncopeptides hosted a webcast March 1, 2021, at 07:30 (CET), including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas Bakker, and CFO Anders Martin-Löf.
Read more

Webcast Year-end Report 2020 presentation

February 18, 2021
Oncopeptides held a webcast February 18, 2021 at 14:00 (CET) when the Year-end Report 2020 and an operational update was presented by CEO Marty J Duvall, CMO Klaas Bakker and CFO Anders Martin-Löf.
Read more

Oncopeptides Virtual Capital Markets Day

November 30, 2020
“Building a Fully Integrated Biotechnology Company”
Read more

Jefferies London Health Care Conference presentation

November 18, 2020
Marty J Duvall presents at Jefferies London Health Care Conference, Wednesday December 18, 2020. The webcast was recorded. See presentation and link
Read more

DNB investor presentation

November 9, 2020
CEO Marty J Duvall presented at DNB Investor Call on November 9, 2020.
Read more

Citi’s 15th Annual BioPharma Virtual Conference – Presentation

September 10, 2020
Oncopeptides' CEO Marty J Duvall and CSO Jakob Lindberg presented at Citi’s 15th Annual BioPharma Virtual Conference. Please see attached presentation.
Read more

Pareto Securities 11:e Healthcare Conference – Presentation

September 2, 2020
Oncopeptides' CEO Marty J Duvall and CSO Jakob Lindberg presented at Pareto Securities Healthcare Conference.
Read more

Webcast regarding operational update Q2 2020

August 26, 2020
Oncopeptides held an operational update Wednesday August 26, 2020. It was presented by CEO Marty J Duvall, CSO Jakob Lindberg and CFO Anders Martin-Löf.
Read more

Nordea Small Cap Seminar – Presentation

August 12, 2020
Oncopeptides presented at Nordea Small Cap Seminar on Aug 12, 2020.
Read more

Jefferies Healthcare Conference June 3, 2020

June 3, 2020
Oncopeptides CEO presents at Jefferies Healthcare Conference at 1.30 – 1.55 PM (EDT) (19.30-19.55 CEST), June 3, 2020.
Read more

Webcast regarding operational update Q1 2020

May 26, 2020
Oncopeptides held an operational update Tuesday May 26, 2020. It was presented by CEO Jakob Lindberg and members of Oncopeptides management team.
Read more

Company Presentation April May 2020

April 27, 2020
Presentation in PDF.
Read more

Company Presentation March April 2020

March 31, 2020
Presentation in PDF
Read more

Stockholm Corporate Finance Life Science Day – presentation

March 11, 2020
Oncopeptides’ CFO Anders Martin-Löf presented at the Stockholm Corporate Finance Life Science Day, March 11, 2020. See the recording of the presentation, and the presentation.
Read more

Webcast Year-End Report 2019

February 20, 2020
CEO Jakob Lindberg presented the Year-End report 2019 and an operational update at a webcast on February 20, 2020.
Read more

Presentation at SEB Annual Pharma & Biotech Seminar 2020

January 22, 2020
CEO Jakob Lindberg presented at SEB Annual Pharma & Biotech Seminar 2020, January 22, 2020.
Read more

2020 J.P. Morgan Health Care Conference – Presentation

January 15, 2020
Oncopeptides AB presented at the 38th Annual J.P. Morgan Healthcare Conference January 13 15, 2020 in San Francisco, US
Read more

Avanza Lunch Presentation

November 27, 2019
Oncopeptides’ CEO Jakob Lindberg presented at the Avanza Lunch meeting November 27, 2019. See the presentation as PDF
Read more

Investing in Oncology Forum 2019

October 7, 2019
Oncopeptides’ CFO Anders Martin-Löf held a presentation at Investing in Oncology Forum 2019 in Stockholm, Sweden, on October 7, 2019.
Read more

Corporate Presentation October 2019

October 3, 2019
Read more

Pareto Health Care Conference 2019

September 5, 2019
Oncopeptides AB (publ) presented at the Pareto Securities Health Care Conference 2019. See attached presentation.
Read more

Corporate Presentation June 17, 2019

June 17, 2019
Read more

REDEYE Growth Day – Presentation

June 10, 2019
Oncopeptides CFO Anders Martin-Löf held a presentation at the REDEYE Growth Day, 10 June 2019. The Presentation was recorded and can be showed at the link below.
Read more

Jefferies 2019 Healthcare Conference, New York – Presentation

June 7, 2019
Oncopeptides CEO Jakob Lindberg gave a presentation at Jefferies Healthcare Conference in New York June 7, at 17.30 CET. The presentation was webcasted, see link below. You can also listen to the presentation, see the MP3 file below.
Read more

REDEYE Pre-ASCO Seminar – presentation

May 28, 2019
CEO Jakob Lindberg presented at the REDEYE Pre-ASCO Seminar, Tuesday May 28, in Stockholm, Sweden. See link to the recording of the presentation below.
Read more

Webcast regarding operational update

May 21, 2019
Oncopeptides held an operational update of the first quarter on Tuesday, May 21, 2019. It was presented by CEO Jakob Lindberg and members of the Oncopeptides management team.
Read more

Webcast regarding clinical program update

April 24, 2019
Oncopeptides held an webcast April 24, 2019, where CEO Jakob Lindberg provided new guidance on the patient recruitment in the OCEAN study and a clinical program update.
Read more

Kempen Life Science Conference 2019 – presentation

April 16, 2019
Oncopeptides' CFO Anders Martin-Löf presented at the Kempen Life Science Conference 2019 in Amsterdam, Netherlands, on April 16, 2019.
Read more

Cowen & Company 39th Annual Health Care Conference – Presentation

March 11, 2019
CEO Jakob Lindberg presented at Cowen and Company 39th Annual Health Care Conference on March 11, 2019. The presentation was webcasted.
Read more

Carnegie Healthcare Conference 2019 – presentation

March 6, 2019
Oncopeptides' CEO Jakob Lindberg presented at Carnegie Healthcare Conference, on March 6, 2019.
Read more

Webcast Year-End Report 2018

February 22, 2019
The Year-end Report for 2018 and an operational update was presented by CEO Jakob Lindberg and members of Oncopeptides management team, February 22, 2019.
Read more

SEB Biotech Seminar – presentation

January 24, 2019
Oncopeptides' CEO Jakob Lindberg presented at the SEB Biotech Seminar, January 24, 2019.
Read more

2019 J.P. Morgan Health Care Conference – Presentation

January 10, 2019
Paula Boultbee CCO and Anders Martin-Löf CFO presented at the 2019 J.P. Morgan Health Care Conference in San Francisco, US, January 7-10, 2019.
Read more

Oncopeptides Capital Markets Day in New York – presentations

December 14, 2018
Oncopeptides did host a Capital Markets Day on December 14th between 8.30-11.00 AM ET in New York, here is the presentation from the whole day.
Read more

DNB Nordic Healthcare Conference 2018 – presentation

December 12, 2018
December 12, CEO Jacob Lindberg held a presentation at the DNB Nordic Healthcare Conference 2018 in Oslo.
Read more

Jakob Lindberg, CEO, Oncopeptides – Company presentation post ASH

December 6, 2018
Jakob Lindberg, CEO, Oncopeptides held a Company presentation post ASH 2018.
Read more

Jefferies 2018 London Healthcare conference – Presentation & webcast

November 14, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies 2018 Healthcare conference in London November 14, 2018. 
Read more

Lunch presentation at DNB

September 25, 2018
Corporate presentation by Jakob Lindberg, CEO, Oncopeptides AB (publ), at DNB 25 September 2018.
Read more

Jefferies Health Care conference, New York – Presentation

June 7, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies Healthcare Conference in New York June 7, 2018.
Read more

Jakob Lindberg, CEO, is interviewed in Di tv

May 17, 2018
Oncopeptides CEO Jakob Lindberg interviewed at DI Börsmorgon (Di tv) about the Q1 Interim report and the future, May 17, 2018.
Read more

Carnegie Healthcare Seminar 2018 – presentation

March 14, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Carnegie Healthcare Seminar on March 14, 2018.
Read more

SCF Life Science Seminarium – presentation

March 7, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Stockholm Corporate Finance Live Science Seminarium March 7 2018.
Read more

ABGSC Orphan Drug Day 2018 – Presentation

February 22, 2018
Oncopeptides presentation at ABGSC Orphan Drug Day at the ABG Office in Stockholm, Sweden, on February 22, 2018.
Read more

Jakob Lindberg interviewed in DI Börsmorgon

January 25, 2018
Oncopeptides CEO Jakob Lindberg is being interviewed in DI Börsmorgon, January 25, 2018.
Read more

JP Morgan, San Francisco – Presentation

January 10, 2018
Oncopeptides' CEO Jakob Lindberg presented at JP Morgan in San Francisco in January 8-10, 2018.
Read more

DNB Nordic Healthcare Conference 2017 – Oslo

December 14, 2017
Oncopeptides’ CEO Jakob Lindberg held a presentation at DNB Nordic Healthcare Conference in Oslo, December 14, 2017.
Read more

Carnegie Healthcare Day in New York – presentation

December 6, 2017
Oncopeptides' CEO Jakob Lindberg held a presentation at Carnegie Healthcare Day in New York on 5 December 2017.
Read more

Lunch at ABG – presentation

November 15, 2017
Jakob Lindberg, CEO of Oncopeptides, held a presentation at ABG on November 15, 2017.
Read more

Pareto Securities Healthcare conference 2017 – Presentation

September 7, 2017
Oncopeptides' CEO Jakob Lindberg presented at Pareto Securities Healthcare conference 2017.
Read more

Annual General Meeting 2017 – Presentation

May 18, 2017
The presentation held by CEO Jakob Lindberg at the Annual General Meeting 2017 at Tändstickspalatset, Stockholm, Sweden.
Read more

DNB SME Conference 2017

April 5, 2017
Oncopeptides' CEO Jakob Lindberg presented at DNB Small & Medium Enterprises Conference on April 5, 2017.
Read more

Carnegie Health Care Seminar

March 16, 2017
Oncopeptides' CEO Jakob Lindberg held a presentation at Carnegie Health Care Conference on March 16, 2017.
Read more

Redeye – Fight cancer-event

March 10, 2017
Jakob Lindberg, CEO of Oncopeptides AB, held a company presentation at the Redeye – Fight cancer-event on March 10, 2017.
Read more

Upcoming events

Oncopeptides via e-mail